PHE885
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$99,377
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $99,377 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $99,377 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE I, OPEN LABEL, STUDY OF B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CAR-T CELLS IN ADULT PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $99,377 | 0 |
Top Doctors Receiving Payments for PHE885
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $99,377 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $99,377
- Total Doctors 0
- Transactions 1
About PHE885
PHE885 is a biological associated with $99,377 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $99,377 was paid across 1 transactions to 0 doctors.
The most common payment nature for PHE885 is "Unspecified" ($99,377, 100.0% of total).
PHE885 is associated with 1 research study, including "PHASE I, OPEN LABEL, STUDY OF B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CAR-T CELLS IN ADULT PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA" ($99,377).